OBJECTIVES: To investigate the associations between the apolipoprotein E (APOE) ε4 allele, carbon dioxide (CO2 ) vasoreactivity, and cognitive performance and to explore the effect of CO2 vasoreactivity and hypertension on the associations between APOE and cognition. DESIGN: Observational. SETTING: Community. PARTICIPANTS: Older adults (N = 625) enrolled in the Maintenance of Balance, Independent Living, Intellect and Zest in the Elderly of Boston Study. MEASUREMENTS: Change in cerebral blood flow velocity in response to CO2 challenge (CO2 ), measured using transcranial Doppler ultrasonography, Trail-Making Test Part B - A (TMT), Hopkins Verbal Learning Test delayed recall (HVLT). RESULTS: APOE-ε4 was associated with lower CO2 vasoreactivity (P = .009) and poorer performance on the TMT (P < .001) and HVLT (P < .001). Having hypertension and APOE-ε4 was associated with worse cognitive and CO2 vasoreactivity measures than having neither or either alone (P < .001 for TMT and HVLT, P = .01 for CO2 vasoreactivity). The association between APOE-ε4 and cognition was only significant if it was present concurrent with low CO2 vasoreactivity, defined as below the median of the sample (APOE by CO2 vasoreactivity interaction: P = .04 for TMT, P = .04 for HVLT). In hypertension, the association between APOE-ε4 and executive function was also only significant in participants with lower CO2 vasoreactivity (P = .005 for APOE by CO2 vasoreactivity). CONCLUSION: Individuals at risk of Alzheimer's disease (AD) because they have APOE-ε4 may have lower CO2 vasoreactivity, which in turn may be contributing to the observed lower cognitive performance associated with this allele. The cognitive effect of APOE-ε4 is magnified in hypertension and low CO2 vasoreactivity. This study offers evidence that APOE-ε4 may be associated with microvascular brain injury even in the absence of clinical AD.
OBJECTIVES: To investigate the associations between the apolipoprotein E (APOE) ε4 allele, carbon dioxide (CO2 ) vasoreactivity, and cognitive performance and to explore the effect of CO2 vasoreactivity and hypertension on the associations between APOE and cognition. DESIGN: Observational. SETTING: Community. PARTICIPANTS: Older adults (N = 625) enrolled in the Maintenance of Balance, Independent Living, Intellect and Zest in the Elderly of Boston Study. MEASUREMENTS: Change in cerebral blood flow velocity in response to CO2 challenge (CO2 ), measured using transcranial Doppler ultrasonography, Trail-Making Test Part B - A (TMT), Hopkins Verbal Learning Test delayed recall (HVLT). RESULTS: APOE-ε4 was associated with lower CO2 vasoreactivity (P = .009) and poorer performance on the TMT (P < .001) and HVLT (P < .001). Having hypertension and APOE-ε4 was associated with worse cognitive and CO2 vasoreactivity measures than having neither or either alone (P < .001 for TMT and HVLT, P = .01 for CO2 vasoreactivity). The association between APOE-ε4 and cognition was only significant if it was present concurrent with low CO2 vasoreactivity, defined as below the median of the sample (APOE by CO2 vasoreactivity interaction: P = .04 for TMT, P = .04 for HVLT). In hypertension, the association between APOE-ε4 and executive function was also only significant in participants with lower CO2 vasoreactivity (P = .005 for APOE by CO2 vasoreactivity). CONCLUSION: Individuals at risk of Alzheimer's disease (AD) because they have APOE-ε4 may have lower CO2 vasoreactivity, which in turn may be contributing to the observed lower cognitive performance associated with this allele. The cognitive effect of APOE-ε4 is magnified in hypertension and low CO2 vasoreactivity. This study offers evidence that APOE-ε4 may be associated with microvascular brain injury even in the absence of clinical AD.
Authors: Robert D Bell; Ethan A Winkler; Itender Singh; Abhay P Sagare; Rashid Deane; Zhenhua Wu; David M Holtzman; Christer Betsholtz; Annika Armulik; Jan Sallstrom; Bradford C Berk; Berislav V Zlokovic Journal: Nature Date: 2012-05-16 Impact factor: 49.962
Authors: S Cantin; M Villien; O Moreaud; I Tropres; S Keignart; E Chipon; J-F Le Bas; J Warnking; A Krainik Journal: Neuroimage Date: 2011-07-01 Impact factor: 6.556
Authors: Edoardo Vicenzini; Maria Chiara Ricciardi; Marta Altieri; Francesco Puccinelli; Novella Bonaffini; Vittorio Di Piero; Gian Luigi Lenzi Journal: Eur Neurol Date: 2007-06-12 Impact factor: 1.710
Authors: Robert S Wilson; Julie A Schneider; Lisa L Barnes; Laurel A Beckett; Neelum T Aggarwal; Elizabeth J Cochran; Elizabeth Berry-Kravis; Julie Bach; Jacob H Fox; Denis A Evans; David A Bennett Journal: Arch Neurol Date: 2002-07
Authors: Leon M Tai; Riya Thomas; Felecia M Marottoli; Kevin P Koster; Takahisa Kanekiyo; Alan W J Morris; Guojun Bu Journal: Acta Neuropathol Date: 2016-02-16 Impact factor: 17.088
Authors: Melanie D Sweeney; Kassandra Kisler; Axel Montagne; Arthur W Toga; Berislav V Zlokovic Journal: Nat Neurosci Date: 2018-09-24 Impact factor: 24.884
Authors: Matthew P Pase; Alexa Beiser; Hugo Aparicio; Charles DeCarli; Ramachandran S Vasan; Joanne Murabito; Sudha Seshadri Journal: Alzheimers Dement Date: 2015-11-02 Impact factor: 21.566
Authors: Sana Suri; Daniel Bulte; Scott T Chiesa; Klaus P Ebmeier; Peter Jezzard; Sebastian W Rieger; Jemma E Pitt; Ludovica Griffanti; Thomas W Okell; Martin Craig; Michael A Chappell; Nicholas P Blockley; Mika Kivimäki; Archana Singh-Manoux; Ashraf W Khir; Alun D Hughes; John E Deanfield; Daria E A Jensen; Sebastian F Green; Veronika Sigutova; Michelle G Jansen; Enikő Zsoldos; Clare E Mackay Journal: Front Physiol Date: 2021-03-31 Impact factor: 4.566
Authors: Aaron R Switzer; Ikreet Cheema; Cheryl R McCreary; Angela Zwiers; Anna Charlton; Ana Alvarez-Veronesi; Ramnik Sekhon; Charlotte Zerna; Randall B Stafford; Richard Frayne; Bradley G Goodyear; Eric E Smith Journal: Neurology Date: 2020-07-08 Impact factor: 9.910